Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theliatinib in advanced solid tumors
NCT02601274Phase 1Terminated
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Theliatinib in solid tumor and esophageal carcinoma, sponsored by Hutchison MediPharma (HMP). Primary endpoint: Incidence of all types/grades of adverse events. Started Apr 2015; status: terminated.
02
Drugs
Theliatinib
03
Conditions
solid tumoresophageal carcinoma
Beyond the preview
Go deeper on NCT02601274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601274.